Published in Antioxid Redox Signal on September 15, 2010
Iron metabolism in the CNS: implications for neurodegenerative diseases. Nat Rev Neurosci (2013) 1.46
Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism. Neurobiol Dis (2012) 1.39
Targeting chelatable iron as a therapeutic modality in Parkinson's disease. Antioxid Redox Signal (2014) 1.29
HCV and oxidative stress in the liver. Viruses (2013) 1.28
Oxidative stress and hepatitis C virus. Virol J (2013) 1.02
Regional siderosis: a new challenge for iron chelation therapy. Front Pharmacol (2013) 0.96
Brain iron homeostasis: from molecular mechanisms to clinical significance and therapeutic opportunities. Antioxid Redox Signal (2013) 0.94
Hypoxia inducible factor-1 as a target for neurodegenerative diseases. Curr Med Chem (2011) 0.91
Iron-dependent functions of mitochondria--relation to neurodegeneration. J Neural Transm (Vienna) (2010) 0.88
Apotransferrin protects cortical neurons from hemoglobin toxicity. Neuropharmacology (2010) 0.87
Promise of neurorestoration and mitochondrial biogenesis in Parkinson's disease with multi target drugs: an alternative to stem cell therapy. Exp Neurobiol (2013) 0.85
Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson's disease after peripheral administration. J Neural Transm (Vienna) (2010) 0.83
Recent advances in amyotrophic lateral sclerosis research: perspectives for personalized clinical application. EPMA J (2010) 0.81
Neuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and β-amyloid in ageing and Alzheimer's disease. Br J Pharmacol (2015) 0.80
Hydroxamic acid-based histone deacetylase (HDAC) inhibitors can mediate neuroprotection independent of HDAC inhibition. J Neurosci (2014) 0.80
New approaches to treating Alzheimer's disease. Perspect Medicin Chem (2015) 0.79
Iron mediates neuritic tree collapse in mesencephalic neurons treated with 1-methyl-4-phenylpyridinium (MPP+). J Neural Transm (Vienna) (2010) 0.79
Effects of selected dietary secondary metabolites on reactive oxygen species production caused by iron(II) autoxidation. Molecules (2014) 0.79
Iron-chelating backbone coupled with monoamine oxidase inhibitory moiety as novel pluripotential therapeutic agents for Alzheimer's disease: a tribute to Moussa Youdim. J Neural Transm (Vienna) (2011) 0.79
Ceruloplasmin deficiency reduces levels of iron and BDNF in the cortex and striatum of young mice and increases their vulnerability to stroke. PLoS One (2011) 0.78
Chronic Iron Limitation Confers Transient Resistance to Oxidative Stress in Marine Diatoms. Plant Physiol (2016) 0.75
Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci (2004) 5.37
Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases. J Nutr Biochem (2004) 1.43
The relevance of iron in the pathogenesis of Parkinson's disease. Ann N Y Acad Sci (2004) 1.42
Role of iron in neurodegenerative disorders. Top Magn Reson Imaging (2006) 1.40
Catechin polyphenols: neurodegeneration and neuroprotection in neurodegenerative diseases. Free Radic Biol Med (2004) 1.34
Involvement of protein kinase C activation and cell survival/ cell cycle genes in green tea polyphenol (-)-epigallocatechin 3-gallate neuroprotective action. J Biol Chem (2002) 1.30
Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. Bioorg Med Chem (2005) 1.27
The relevance of iron in the pathogenesis of Parkinson's disease. J Neurochem (2011) 1.26
Cell signaling pathways in the neuroprotective actions of the green tea polyphenol (-)-epigallocatechin-3-gallate: implications for neurodegenerative diseases. J Neurochem (2004) 1.24
Gene expression profiling of sporadic Parkinson's disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70. Ann N Y Acad Sci (2005) 1.23
Multifunctional activities of green tea catechins in neuroprotection. Modulation of cell survival genes, iron-dependent oxidative stress and PKC signaling pathway. Neurosignals (2005) 1.21
Green tea catechins as brain-permeable, natural iron chelators-antioxidants for the treatment of neurodegenerative disorders. Mol Nutr Food Res (2006) 1.21
Metallocorroles as cytoprotective agents against oxidative and nitrative stress in cellular models of neurodegeneration. J Neurochem (2010) 1.19
Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives. Brain Res Brain Res Rev (2005) 1.17
A molecular signature in blood identifies early Parkinson's disease. Mol Neurodegener (2012) 1.13
Targeting multiple neurodegenerative diseases etiologies with multimodal-acting green tea catechins. J Nutr (2008) 1.12
Neuroprotective molecular mechanisms of (-)-epigallocatechin-3-gallate: a reflective outcome of its antioxidant, iron chelating and neuritogenic properties. Genes Nutr (2009) 1.12
Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog Neurobiol (2010) 1.11
Attenuation of 6-hydroxydopamine (6-OHDA)-induced nuclear factor-kappaB (NF-kappaB) activation and cell death by tea extracts in neuronal cultures. Biochem Pharmacol (2002) 1.10
Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. FASEB J (2005) 1.09
Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J Neurosci Res (2004) 1.08
Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan. Neurotox Res (2009) 1.04
Cell signaling pathways and iron chelation in the neurorestorative activity of green tea polyphenols: special reference to epigallocatechin gallate (EGCG). J Alzheimers Dis (2008) 1.04
Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats. Neuropharmacology (2004) 1.03
Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis. FASEB J (2009) 1.03
Neuroprotective strategies in Parkinson's disease : an update on progress. CNS Drugs (2003) 1.02
Simultaneous manipulation of multiple brain targets by green tea catechins: a potential neuroprotective strategy for Alzheimer and Parkinson diseases. CNS Neurosci Ther (2008) 1.02
Multifunctional drugs with different CNS targets for neuropsychiatric disorders. J Neurochem (2006) 0.99
Striatal dopa and glucose metabolism in PD patients with freezing of gait. Mov Disord (2006) 0.99
Redox imbalance. Cell Tissue Res (2004) 0.98
Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. FASEB J (2004) 0.98
Manganese corroles prevent intracellular nitration and subsequent death of insulin-producing cells. ACS Chem Biol (2009) 0.98
Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci Lett (2004) 0.97
A novel role for glyceraldehyde-3-phosphate dehydrogenase and monoamine oxidase B cascade in ethanol-induced cellular damage. Biol Psychiatry (2009) 0.97
Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators. Free Radic Biol Med (2013) 0.95
Iron-binding characteristics of neuromelanin of the human substantia nigra. Biochem Pharmacol (2003) 0.95
Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. FASEB J (2007) 0.95
Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease. J Neurochem (2006) 0.95
A novel approach of proteomics and transcriptomics to study the mechanism of action of the antioxidant-iron chelator green tea polyphenol (-)-epigallocatechin-3-gallate. Free Radic Biol Med (2007) 0.95
Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan. J Neurochem (2002) 0.94
Understanding the broad-spectrum neuroprotective action profile of green tea polyphenols in aging and neurodegenerative diseases. J Alzheimers Dis (2011) 0.93
Binding preference of p62 towards LC3-ll during dopaminergic neurotoxin-induced impairment of autophagic flux. Autophagy (2011) 0.92
Rasagiline in Parkinson's disease. N Engl J Med (2010) 0.92
cDNA gene expression profile homology of antioxidants and their antiapoptotic and proapoptotic activities in human neuroblastoma cells. FASEB J (2003) 0.92
Iron dysregulation in Alzheimer's disease: multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents. Prog Neurobiol (2007) 0.92
Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate. J Mol Neurosci (2004) 0.92
Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30. Neurotox Res (2009) 0.92
An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci Lett (2002) 0.92
Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline. Br J Pharmacol (2004) 0.91
Early and late gene changes in MPTP mice model of Parkinson's disease employing cDNA microarray. Neurochem Res (2002) 0.91
Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro. J Neurochem (2007) 0.91
Neurorescue activity, APP regulation and amyloid-beta peptide reduction by novel multi-functional brain permeable iron- chelating- antioxidants, M-30 and green tea polyphenol, EGCG. Curr Alzheimer Res (2007) 0.91
Site-activated chelators targeting acetylcholinesterase and monoamine oxidase for Alzheimer's therapy. ACS Chem Biol (2010) 0.90
Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators. FASEB J (2007) 0.90
The neuroprotective effect of Activin A and B: implication for neurodegenerative diseases. J Neurochem (2007) 0.90
Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression. Psychopharmacology (Berl) (2002) 0.90
Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor. J Neurochem (2003) 0.90
Green tea polyphenol (-) -epigallocatechin-3-gallate promotes the rapid protein kinase C- and proteasome-mediated degradation of Bad: implications for neuroprotection. J Neurochem (2006) 0.89